GCGR antibody and GLP-1 fusion protein thereof, pharmaceutical composition thereof and application thereof
US11542336B2 · kind B2 · utility
0Cited by
20References
7Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Mar 19, 2019 |
| Grant date | Jan 3, 2023 |
| Priority date | — |
| Expiry date | Mar 19, 2039 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2319/33
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Provided herein are a glucagon receptor (GCGR) antibody and its fusion protein with glucagon-like peptide-1 (GLP-1), and a pharmaceutical composition thereof. Also provided herein is a method for using the GCGR antibody and its fusion protein with GLP-1 to treat, prevent or improve one or more symptoms of hyperglycemia, type 2 diabetes, metabolic syndrome or dyslipidemia.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.